Literature DB >> 17045629

Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem.

Stavros K Ntoumazios1, Paraskevi V Voulgari, Konstantinos Potsis, Evagelos Koutis, Niki Tsifetaki, Dimitrios A Assimakopoulos.   

Abstract

OBJECTIVES: Systemic sclerosis (SSc) is a multisystem disease characterized by abnormalities of small blood vessels, and fibrosis of the skin and internal organs including gastrointestinal tract. This article reviews the esophageal involvement in SSc, emphasizing the gastroesophageal reflux, which is a common problem in SSc patients.
METHODS: We conducted a Medline search from 1966 to 2005. The keywords "systemic sclerosis," "esophageal involvement," "gastroesophageal reflux," "esophagitis," and "treatment" were used.
RESULTS: The gastrointestinal tract is frequently affected in diffuse and limited disease. Although any part of the gastrointestinal tract can be involved, esophageal disease occurs in nearly all patients with SSc. Common esophageal manifestations in SSc include motility abnormalities and gastroesophageal reflux (GER), Barrett's esophagus, adenocarcinoma, infectious esophagitis, and drug-induced esophagitis. Common complications of GER include esophagitis with erosions and bleeding and stricture formation. Extraesophageal manifestations of GER include mouth ulcers, chronic cough, hoarse voice, sore throat, pharyngitis, laryngospasm, asthma, and recurrent pneumonia. Diagnostic procedures used in the investigation of esophageal involvement include barium esophagram, esophageal manometry, 24-hour ambulatory pH, and endoscopy. Treatment of GER in SSc includes behavioral modification and medical therapy, mainly with proton pump inhibitors. Surgical intervention has a limited role in the management of GER in selected SSc patients.
CONCLUSIONS: Esophageal involvement is frequent in SSc patients. Gastroesophageal reflux may cause high morbidity. Careful examination of the patients reveals gastrointestinal abnormalities even in patients without symptoms. Appropriate treatment of esophageal involvement ameliorates symptoms and prevents complications.

Entities:  

Mesh:

Year:  2006        PMID: 17045629     DOI: 10.1016/j.semarthrit.2006.08.002

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  28 in total

1.  [Gastrointestinal involvement in systemic sclerosis. An underestimated complication].

Authors:  P Saar; T Schmeiser; I H Tarner; U Müller-Ladner
Journal:  Hautarzt       Date:  2007-10       Impact factor: 0.751

2.  Oropharyngolaryngeal disorders in scleroderma: development and validation of the SLS scale.

Authors:  Chiara Vitali; Elisa Borghi; Arianna Napoletano; Francesca Polini; Monica Caronni; Paola Ammenti; Davide Cattaneo
Journal:  Dysphagia       Date:  2009-08-26       Impact factor: 3.438

3.  Videofluorography swallow study of patients with systemic sclerosis.

Authors:  S Russo; G Lo Re; M Galia; A Reginelli; V Lo Greco; T D'Agostino; G La Tona; F Coppolino; R Grassi; M Midiri; R Lagalla
Journal:  Radiol Med       Date:  2009-06-26       Impact factor: 3.469

Review 4.  Dysphagia in the Elderly.

Authors:  Scott M Smukalla; Irina Dimitrova; Jeremy M Feintuch; Abraham Khan
Journal:  Curr Treat Options Gastroenterol       Date:  2017-09

5.  Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.

Authors:  D Sánchez-Cano; N Ortego-Centeno; J L Callejas; V Fonollosa Plá; R Ríos-Fernández; C Tolosa-Vilella; G Espinosa-Garriga; D Colunga-Argüelles; M V Egurbide-Arberas; M Rubio-Rivas; M Freire; J J Ríos-Blanco; L Trapiella-Martínez; M Rodríguez-Carballeira; A Marín-Ballvé; X Pla-Salas; C P Simeón-Aznar
Journal:  Rheumatol Int       Date:  2018-01-10       Impact factor: 2.631

6.  Anti-vinculin antibodies in scleroderma (SSc): a potential link between autoimmunity and gastrointestinal system involvement in two SSc cohorts.

Authors:  Yossra Suliman; Suzanne Kafaja; Sunny J Oh; Mohamed Alemam; Gianluca Bagnato; Giuseppina Abignano; Ram Raj Singh; Gillian Barlow; Xiaochen Liu; Isela Valera; Walter Morales; Ali Rezaie; Mark Pimentel; Francesco Del Galdo; Daniel E Furst
Journal:  Clin Rheumatol       Date:  2020-11-24       Impact factor: 2.980

7.  Beneficial effect of the 5-HT1A receptor agonist buspirone on esophageal dysfunction associated with systemic sclerosis: A pilot study.

Authors:  George P Karamanolis; Stylianos Panopoulos; Anastasios Karlaftis; Konstantinos Denaxas; Dimitrios Kamberoglou; Petros P Sfikakis; Spiros D Ladas
Journal:  United European Gastroenterol J       Date:  2015-06       Impact factor: 4.623

8.  Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study.

Authors:  Linda Kwakkenbos; Brett D Thombs; Dinesh Khanna; Marie-Eve Carrier; Murray Baron; Daniel E Furst; Karen Gottesman; Frank van den Hoogen; Vanessa L Malcarne; Maureen D Mayes; Luc Mouthon; Warren R Nielson; Serge Poiraudeau; Robert Riggs; Maureen Sauvé; Fredrick Wigley; Marie Hudson; Susan J Bartlett
Journal:  Rheumatology (Oxford)       Date:  2017-08-01       Impact factor: 7.580

Review 9.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01

10.  Abnormal esophageal acid exposure on high-dose proton pump inhibitor therapy is common in systemic sclerosis patients.

Authors:  E K Stern; D A Carlson; S Falmagne; A D Hoffmann; M Carns; J E Pandolfino; M Hinchcliff; D M Brenner
Journal:  Neurogastroenterol Motil       Date:  2017-11-06       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.